In Re: Cardizem Cd Antitrust Litigation’s Empirical Analysis
2003
Citation profile
11 district · 1 state decisions
How this case has been cited
Cited by 46 later decisions — most recently September 2022 · most notably 338 F. Supp. 2d 517 - In Re K-Dur Antitrust Litigation (2004), 289 F. Supp. 2d 986 - Asahi Glass Co., Ltd. v. Pentech Pharmaceuticals (2003)
11 district · 1 state decisions
Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.
Relationships
Relies on United States v. Socony-Vacuum Oil Co. · Brunswick Corporation v. Pueblo Bowl-O-Mat Inc · Associated General Contractors of California, Inc. v. California State Council of Carpenters · Northern Pacific Railway Co. v. United States · Continental Inc v. Gte Sylvania Incorporated
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 46 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“[A]lthough it is clear ... that in a federal multidistrict litigation there is a preference for applying the law of the transferee district, see In re Temporomandibular Joint (TMJ) Implants Prod. Liab. Litig., 97 F.3d 1050 (8th Cir.1996); Menowitz v. Brown, 991 F.2d 36 (2d Cir.1993), it is not clear that precedent "unique" to a particular circuit and arguably divergent from the predominant interpretation of a federal law, such as the Sixth Circuit's "necessary predicate" gloss on the antitrust injury doctrine, should be applied to state antitrust laws or federal antitrust claims that originated in other circuits, see In re Korean Air Lines Disaster of Sept. 1, 1983, 829 F.2d 1171 (D.C.Cir.1987).”
5 later decisions quote this exact passage · from the majority“a classic example of a per se illegal restraint of trade’’); Andrx Pharms., Inc. v. Biovail Corp. Int'l, 256 F.3d 799, 811 (D.C.Cir.2001) (holding that a reverse payment agreement”
2 later decisions quote this exact passage · from the majority“(1) ... In determining whether Plaintiffs have properly pled antitrust injury, does the language of the Sixth Circuit’s decisions in Valley Products Co. v. Landmark, 128 F.3d 398, 404 (6th Cir. 1997) and Hodges v. WSM, Inc., 26 F.3d 36, 39 (6th Cir.1994) require dismissal of Plaintiffs’ antitrust claims at the pleading stage if Plaintiffs cannot allege facts showing that Defendants’ alleged anti-competitive conduct was a “necessary predicate” to their antitrust injury; i.e., that dismissal is required unless Plaintiffs plead facts showing that the alleged antitrust injury could not possibly have occurred absent Defendants’ alleged anticompetitive conduct? (2) ... In determining whether Plaintiffs’ motions for partial judgment were properly granted, whether the Defendants’ September 24, 1997 Agreement constitutes a restraint of trade that is illegal per se under section 1 of the Sherman Antitrust Act, 15 U.S.C. § 1 , and under the corresponding state antitrust laws at issue in this litigation.”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.